Meanwhile, Ad-periaxin did not obviously alter the numbers of MyHC-I- and MyHC-II-positive fibers (Fig. 1A–D), indicating that gene therapy targeting L-periaxin in skeletal muscle alone could not be an effective treatment strategy for CMT4F-associated muscle atrophy. Here, PRX is linked to Charcot-Marie-Tooth disease type 4F.